Immune complex pathophysiology

Annals of the New York Academy of Sciences

Volumn 1109, Issue , 2007, Pages 66-83

  Nydegger, Urs E ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b Transfusion Therapy Consultancy TTC   (Switzerland)

Author keywords

Complement; Fc receptor; Immune complex

Indexed keywords

ANTIBODY; COMPLEMENT; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTHUS PHENOMENON; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; EFFECTOR CELL; EQUILIBRIUM CONSTANT; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; PATHOPHYSIOLOGY; RETICULOENDOTHELIAL SYSTEM; SERUM SICKNESS; ANIMAL; ARTICLE; BLOOD; IMMUNOLOGY; PATHOLOGY; PHYSICAL CHEMISTRY; PROTEIN ENGINEERING;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; ARTHUS REACTION; CHEMISTRY, PHYSICAL; CYTOKINES; HUMANS; IMMUNE SYSTEM DISEASES; PROTEIN ENGINEERING;

EID: 34848925771     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1398.009     Document Type: Conference Paper

References (79)

1. CALAME, K. 2006. Transcription factors that regulate memory in human responses. Immunol. Rev. 211: 269-279.
2. HEYMAN, B. 2000. Regulation of antibody responses via antibodies, complement, and Fc receptors. Ann. Rev. Immunol. 18: 709-737.
3. SAAD, A-F. et al. 2006. OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages. J. Lipid Res. 47: 1975-1983.
4. OHMIT, S.E. et al. 2006. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccine. N. Engl. J. Med. 355: 2513-2522.
5. LAMBERT, P.H., M. LIU & C.A. SIEGRIST. 2005. Can successful vaccines teach us how to induce efficient protective immune responses? Nat. Med. 11: S54-S62.
6. KOBASA, D. et al. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-323.
7. SCHULZE-LUEHRMANN, J. & S. GHOSH. 2006. Antigen-receptor signaling to nuclear factor kappa B. Immunity 25: 701-715.
8. SCHNARE, M. et al. 2001. Toll-like receptors control activation of adaptive immune response. Nat. Immunol. 2: 947-950.
9. GAVIN, A.L. et al. 2006. Adjuvant-enhanced antibody responses in the absence of toll-like receptor. Science 314: 1936-1938.
10. OGUNNIYI, A.D. et al. 2007. Development of a vaccine against invasive Pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 75: 350-357.
11. AYDAR, Y. et al. 2005. The influence of immune complex-bearing follicular dendritic cells on the IgM response, Ig class switching, and production of high affinity IgG. J. Immunol. 174: 5358-5366.
12. REFAELI, Y. et al. 2005. The protooncogene MYC can break B cell tolerance. Proc. Natl. Acad. Sci. USA 102: 4097-4102.
13. SILVERSTEIN, A.M. 2003. Splitting the difference: the germline-somatic mutation debate on generating antibody diversity. Nat. Immunol. 4: 829-833.
14. AKSU, G. et al. 2006. Serum immunoglobulin (IgG, IgM, IgA) and IgG subclass concentrations in healthy children: a study using nephelometric technique. Turk. J. Pediatr. 48: 19-24.
15. ZARRIN, A.A. et al. 2007. Antibody class switching mediated by yeast endonuclease-generated DNA breaks. Science 315: 377-384.
16. LEBON, A. et al. 2006. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176: 2074-2078.
17. VITETTA, E.S. & V.F. GHETIE. 2006. Considering therapeutic antibodies. Science 313: 308-309.
18. REMAUT, H. & G. WAKSMAN. 2006. Protein-protein interaction through β-strand addition. Trends Biochem. Sci. 31: 436-444.
19. VALADON, P. et al. 2006. Screening phage display libraries for organ-specific vascular immunotargeting in vivo. Proc. Natl. Acad. Sci. USA 103: 407-412.
20. DEBERNARDIS, F. et al. 2007. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelia and protect against experimental vaginal candidiasis. J. Infect. Dis. 195: 149-157.
21. JANEWAY, C.A. et al. 1999. Immunobiology Elsevier. London.
22. BRADEN, B.C. et al. 1995. Protein motion and lock and key comlementarity in antigen antibody reactions. Pharmaceutica Acta Helvetiae 69: 225-230.
23. DEJAEGERE, A. et al. 2005. Variations in antigen-antibody association kinetics as a function of pH and salt concentrations: a QSAR and molecular modeling study. Biochemistry 44: 14409-14418.
24. LEGER, R.M. et al. 1998. False-positive eluate reactivity due to low-ionic wash solution used with commercial acid-elution kits. Transfusion 38: 565-572.
25. HEGER, A. et al. 2007. S/D treatment of plasma leads to immune complex dissolution. SFTS Tours (France) Poster P140.
26. MOROZOV, A.V. & T. KORTEMME. 2006. Potential functions for hydrogen bonds in protein structure prediction and design. Adv. Protein Chem. 72: 1-38.
27. YOUNG, T. et al. 2007. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc. Natl. Acad. Sci. USA 104: 808-813.
28. CHO, K. et al. 2006. Specificity of molecular interactions in transient proteinprotein interaction interfaces. Proteins 65: 593-606.
29. JEFFERSON, E.R., T.P. WALSH & G.J. BARTON. 2006. Biological units and their effect upon the properties and prediction of protein-protein interactions. J. Mol. Biol. 364: 1118-1129.
30. KANEKO, Y., F. NIMMERJAHN & J.V. RAVETCH. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
31. SAVIRANTA, P. & O. KALLIONIEMI. 2006. Human protein atlas charts a diverse terrain. Trends Biochem. Sci. 24: 195-197.
32. FISCHER, E. et al. 2006. Identification of a peptide mimicking the binding pattern of an antiphospholipid antibody. Immunobiology 211: 695-699.
33. BUI, H.H. et al. 2007. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl. Acad. Sci. USA 104: 246-251.
34. RIEBEN, R. et al. 1991. Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons at different age categories. Transfusion 31: 607-680.
35. BUONOMANO, R. et al. 1999. Quantitation and characterization of anti-Galalpha1-3Gal antibodies in sera of 200 healthy persons. Xenotransplantation 6: 173-180.
36. HEAP, C.J. et al. 2005. Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J. Gen. Virol. 86: 1791-1800.
37. KADIRVELRAJ, R. et al. 2006. Understanding the bacterial polysaccharide antigenicity of Streptococcus agalactiae versus Streptococcus pneumoniae. Proc. Natl. Acad. Sci. USA 103: 8149-8154.
38. GONZALEZ-OUTEIRINO, J., R. KADIRVELRAJ & R.J. WOODS. 2005. Structural elucidation of type III group B Streptococcus capsular polysaccharide using molecular dynamics simulations: the role of sialic acid. Carbohydr. Res. 340: 1007-1018.
39. COTRAN, R.S., K. VINAY & T. COLLINS. 1999. Pathologic Basis of Disease. W.B. Saunders. Philadelphia. PA.
40. STORCH, W.B. 2000. Immunofluorescence in Clinical Immunology. A Primer and Atlas. Birkhaeuser. Basel.
41. ASAKA, M. et al. 2006. The expression and localization of osteopontin in the mouse major salivary glands. Arch. Histol. Cytol. 69: 181-188.
42. VASHIST, S.K. et al. 2006. Demonstration of a new biosensing concept for immunodiagnostic applications based on change in surface conductance of antibodies after biomolecular interactions. J. Zhejiang Univ. Sci. B. 7: 683-685.
43. KAITO, M. et al. 2006. Immune complex of hepatitis C virus particles detected by immunogold electron microscopy. J. Gastroenterol. 41: 807-808.
44. CREIGHTON, W.D., P.H. LAMBERT & P.A. MIESCHER. 1973. Detection of antibodies and soluble antigen-antibody complexes by precipitation with polyethylene glycol. J. Immunol. 111: 1219-1227.
45. NYDEGGER, U.E. et al. 1974. Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q. J. Clin. Invest. 54: 297-309.
46. ZLATAROVA, A.S. et al. 2006. Existence of different but overlapping IgG- and IgM-binding sites on the globular heads of human C1q. Biochemistry 45: 9979-9988.
47. CHOI, J.W. et al. 2006. Application of complement 1q for the site-selective recognition of immune complex in protein chip. Biosens. Bioelectron. 22: 764-767.
48. GAO, H. et al. 2006. Adenoviral-mediated overexpression of SOCS3 enhances IgG immune complex-induced acute lung injury. J. Immunol. 177: 612-620.
49. DAS, U.N. 2006. Clinical laboratory tools to diagnose inflammation. Adv. Clin. Chem. 41: 189-229.
50. KIRSCHFINK, M. & T.E. MOLLNES. 2003. Modern complement analysis. Clin. Diagn. Lab. Immunol. 982-989.
51. STANFIELD, R.L. et al. 2006. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 80: 6093-6105.
52. KELTON, J.G. 2005. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 127: 9S-20S.
53. CRAIG, M.L., J.N. WAITUMBI & R.P. TAYLOR. 2005. Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1. J. Immunol. 174: 3059-3066.
54. YEUNG, T. et al. 2006. Lipid metabolism and dynamics during phagocytosis. Curr. Opin. Cell Biol. 18: 429-437.
55. NIMMERJAHN, F. & J.V. RAVETCH. 2006. Fc receptors: old friends and new family members. Immunity 24: 19-28.
56. BAUCH, A. & G. SUPERTI-FURGA. 2006. Charting protein complexes, signaling pathways, and networks in the immune system. Immunol. Rev. 210: 187-207.
57. BAUER, J.W. et al. 2006. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 3: e491.
58. MILES, S.A. et al. 2005. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 201: 747-754.
59. SUTTERWALA, F.S. et al. 1997. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J. Exp. Med. 185: 1977-1985.
60. MARX, J. 2007. Puzzling out the pains in the gut. Science 315: 33-35.
61. BOYMAN, O. et al. 2006. Selective stimulation of T cell subsets with antibodycytokine immune complexes. Science 311: 1924-1927.
62. PRLIC, M. & M.J. BEVAN. 2006. An antibody paradox, resolved. Science 311: 1875-1876.
63. MULLAZEHI, M. et al. 2007. High anti-collagen type II antibody levels and induction of pro-inflammatory cytokines by anti-collagen antibody containing immune complexes in vitro characterize a distinct RA phenotype associated with acute inflammation at the time of disease onset. Ann. Rheum. Dis. 66(4): 537-541.
64. BORG, F.A. & D.A. ISENBERG. 2007. Syndromes and complications of interferon therapy. Curr. Opin. Rhematol. 19: 61-66.
65. YOON, J.S. et al. 2006. Effects of intravenous immunoglobulin and methylprednisolone on human umbilical vein endothelial cells in vitro. Immunobiology 2115.
66. TEDGUI, A. & Z. MALLAT. 2006. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86: 515-581.
67. VAN DE VELDE, N.C., P.L. MOTTRAM & P.M. HOGARTH. 2006. FcgammaRII and multisystem autoimmune disease. Springer Semin. Immunopathol. 28: 329-338.
68. LISTER, K.J. & M.J. HICKEY. 2006. Immune complexes alter cerebral microvessel permeability: roles of complement and leukocyte adhesion. Am. J. Physiol. Heart Circ. Physiol. 291: H694-H704.
69. HORN, J. et al. 2007. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin. Immunol. 122: 156-162.
70. CLARK, B.M. et al. 2006. Severe serum sickness reaction to oral and intramuscular penicillin. Pharmacotherapy 26: 705-708.
71. NYDEGGER, U.E. 2005. Immune Complexes. In Kelley's Textbook of Rheumatology, Vol. I. E.D. Harrys, et al., Eds.: 332-341. Elsevier Saunders. Philadelphia. PA.
72. STAHL, D. & W. SIBROWSKI. 2006. IgG2 containing IgM-IgG immune complexes predominate in normal human plasma, but not in plasma of patients with warm autoimmune haemolytic anaemia. Eur. J. Haematol. 77: 191-202.
73. SIRAGAM, V. et al. 2005. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J. Clin. Invest. 115: 155-160.
74. CLYNES, R. 2005. Immune complexes as therapy for autoimmunity. J. Clin. Invest. 115: 25-27.
75. NYDEGGER, U.E., G.F. RIEDLER & W.A. FLEGEL. 2007. Histoblood groups other than HLA in organ transplantation. Transpl. Proc. 39: 64-68.
76. LEMIEUX, R. & R. BAZIN. 2006. Autoantibody-induced formation of immune complexes in normal human serum. Curr. Pharm. Des. 12: 173-179.
77. MIESCHER, S.M. et al. 2005. Comparative analysis of antigen specificities in the monomeric and dimeric fractions of intravenous immunoglobulin. Ann. N. Y. Acad. Sci. 1051: 582-590.
78. KANEKO, Y. et al. 2006. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203: 789-.
79. WHICHER, J.T. 1998. Cryoglobulin. In Encyclopedia of Immunology, Vol. 2. P.J. Delves & I.M. Roitt, Eds.: 665-557. Academic Press. San Diego.